BioSpace News Archive

Helix BioPharma Corp. (TSX: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July 31, 2019.

111, Inc. (NASDAQ: YI) (“111" or the “Company”), a leading integrated online and offline healthcare platform in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2019, before the open of U.S. markets on Thursday, November 14, 2019.

The American Academy of Orthopaedic Manual Physical Therapists (AAOMPT) has released a position statement opposing “degenerative disc disease” as a diagnostic term for the cause of neck and back pain.

The Prix Galien USA Committee last night honored excellence in the biopharmaceutical and medical industry for research, development and innovation at its 13th annual Prix Galien Awards Gala, held at the American Museum of Natural History in New York City.

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today released interim clinical trial results presented at the American Society for Dermatologic Surgery (“ASDS”) Annual Meeting on October 24, 2019.

Acknowledging the one-year anniversary of the signing of HR 6—the historic federal legislation aimed at curbing the opioid epidemic, DisposeRx is well on its way to making good on its pledge to remove over 10 million opioid pills from our nation’s medicine cabinets.

Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has entered into a $20.0 million common stock purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor.

BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced the pricing of its public offering of 1,851,852 ordinary shares at a public offering price of $13.50 per share

Nearly two years of real-world outcomes data on Abiomed’s Impella RP heart pump shows that when physicians followed the FDA’s approved protocol for Impella RP use they achieved 72% patient survival and 98% native heart recovery.

US-based medical device company and manufacturer of the NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses Visioneering Technologies, Inc (ASX: VTI) (‘Visioneering’ or ‘the Company’) will be presenting the science behind the NaturalVue® Multifocal (etafilcon A) 1 Day Contact Lens with a poster on Friday, October 25.